{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T01:06:45Z","timestamp":1770340005975,"version":"3.49.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2020,7,9]],"date-time":"2020-07-09T00:00:00Z","timestamp":1594252800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,7,9]],"date-time":"2020-07-09T00:00:00Z","timestamp":1594252800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s40264-020-00960-1","type":"journal-article","created":{"date-parts":[[2020,7,9]],"date-time":"2020-07-09T16:06:43Z","timestamp":1594310803000},"page":"1267-1276","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["An Evaluation of Postmarketing Reports of Serious Idiosyncratic Liver Injury Associated with Ulipristal Acetate for the Treatment of Uterine Fibroids"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5603-9359","authenticated-orcid":false,"given":"Sarah","family":"Kang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allen","family":"Brinker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. Christopher","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lara","family":"Dimick-Santos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark I.","family":"Avigan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,7,9]]},"reference":[{"issue":"1","key":"960_CR1","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1111\/tog.12072","volume":"16","author":"M Murdoch","year":"2014","unstructured":"Murdoch M, Roberts M. Selective progesterone receptor modulators and their use within gynaecology. Obstet Gynaecol. 2014;16(1):46\u201350. https:\/\/doi.org\/10.1111\/tog.12072.","journal-title":"Obstet Gynaecol"},{"key":"960_CR2","unstructured":"Stewart EA, Laughlin-Tommaso SK. Uterine leiomyoma (fibroids): epidemiology, clinical features, diagnosis, and natural history. Waltham (MA): UpToDate Inc. https:\/\/www.uptodate.com. Accessed 1 Jun 2017."},{"issue":"11","key":"960_CR3","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1080\/03007995.2017.1372107","volume":"33","author":"AM Soliman","year":"2017","unstructured":"Soliman AM, Margolis MK, Castelli-Haley J, Fuldeore MJ, Owens CD, Coyne KS. Impact of uterine fibroid symptoms on health-related quality of life of US women: evidence from a cross-sectional survey. Curr Med Res Opin. 2017;33(11):1971\u20138. https:\/\/doi.org\/10.1080\/03007995.2017.1372107.","journal-title":"Curr Med Res Opin"},{"issue":"3","key":"960_CR4","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1093\/biolre\/iox094","volume":"97","author":"M Ali","year":"2017","unstructured":"Ali M, Al-Hendy A. Selective progesterone receptor modulators for fertility preservation in women with symptomatic uterine fibroids. Biol Reprod. 2017;97(3):337\u201352. https:\/\/doi.org\/10.1093\/biolre\/iox094.","journal-title":"Biol Reprod"},{"issue":"5","key":"960_CR5","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1016\/j.fertnstert.2011.08.021","volume":"96","author":"P Bouchard","year":"2011","unstructured":"Bouchard P, Chabbert-Buffet N, Fauser BC. Selective progesterone receptor modulators in reproductive medicine: pharmacology, clinical efficacy and safety. Fertil Steril. 2011;96(5):1175\u201389. https:\/\/doi.org\/10.1016\/j.fertnstert.2011.08.021.","journal-title":"Fertil Steril"},{"issue":"2","key":"960_CR6","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/S0959-8049(98)00388-8","volume":"35","author":"JF Robertson","year":"1999","unstructured":"Robertson JF, Willsher PC, Winterbottom L, Blamey RW, Thorpe S. Onapristone, a progesterone receptor antagonist, as first-line therapy in primary breast cancer. Eur J Cancer. 1999;35(2):214\u20138.","journal-title":"Eur J Cancer"},{"issue":"9","key":"960_CR7","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1080\/17425255.2018.1506766","volume":"14","author":"M Ali","year":"2018","unstructured":"Ali M, Al-Hendy A. Uterine fibroid therapy: the pharmacokinetic considerations. Expert Opin Drug Metab Toxicol. 2018;14(9):887\u20139. https:\/\/doi.org\/10.1080\/17425255.2018.1506766.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"4","key":"960_CR8","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1002\/hep.22177","volume":"47","author":"WM Lee","year":"2008","unstructured":"Lee WM, Squires RH Jr, Nyberg SL, Doo E, Hoofnagle JH. Acute liver failure: summary of a workshop. Hepatology. 2008;47(4):1401\u201315. https:\/\/doi.org\/10.1002\/hep.22177.","journal-title":"Hepatology"},{"issue":"3","key":"960_CR9","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1056\/NEJMra1816149","volume":"381","author":"JH Hoofnagle","year":"2019","unstructured":"Hoofnagle JH, Bjornsson ES. Drug-induced liver injury: types and phenotypes. N Engl J Med. 2019;381(3):264\u201373. https:\/\/doi.org\/10.1056\/NEJMra1816149.","journal-title":"N Engl J Med"},{"key":"960_CR10","unstructured":"US Food and Drug Administration. Guidance for industry: drug-induced liver injury: premarketing clinical evaluation. https:\/\/www.fda.gov\/media\/116737\/download. Accessed Jul 2009."},{"key":"960_CR11","volume-title":"Drug-induced liver disease hepatotoxicity: the adverse effects of drugs and other chemicals on the liver","author":"HJ Zimmerman","year":"1999","unstructured":"Zimmerman HJ. Drug-induced liver disease hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 1999.","edition":"2"},{"issue":"2","key":"960_CR12","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1002\/hep.20800","volume":"42","author":"E Bjornsson","year":"2005","unstructured":"Bjornsson E, Olsson R. Outcome and prognostic markers in severe drug-induced liver disease. Hepatology. 2005;42(2):481\u20139. https:\/\/doi.org\/10.1002\/hep.20800.","journal-title":"Hepatology"},{"issue":"5","key":"960_CR13","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1056\/NEJMoa1103182","volume":"366","author":"J Donnez","year":"2012","unstructured":"Donnez J, Tatarchuk TF, Bouchard P, Puscasiu L, Zakharenko NF, Ivanova T, et al. Ulipristal acetate versus placebo for fibroid treatment before surgery. N Engl J Med. 2012;366(5):409\u201320. https:\/\/doi.org\/10.1056\/NEJMoa1103182.","journal-title":"N Engl J Med"},{"issue":"5","key":"960_CR14","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1056\/NEJMoa1103180","volume":"366","author":"J Donnez","year":"2012","unstructured":"Donnez J, Tomaszewski J, Vazquez F, Bouchard P, Lemieszczuk B, Baro F, et al. Ulipristal acetate versus leuprolide acetate for uterine fibroids. N Engl J Med. 2012;366(5):421\u201332. https:\/\/doi.org\/10.1056\/NEJMoa1103180.","journal-title":"N Engl J Med"},{"issue":"6","key":"960_CR15","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1016\/j.fertnstert.2014.02.008","volume":"101","author":"J Donnez","year":"2014","unstructured":"Donnez J, Vazquez F, Tomaszewski J, Nouri K, Bouchard P, Fauser BC, et al. Long-term treatment of uterine fibroids with ulipristal acetate. Fertil Steril. 2014;101(6):1565\u201373. https:\/\/doi.org\/10.1016\/j.fertnstert.2014.02.008(e1\u201318).","journal-title":"Fertil Steril."},{"issue":"2","key":"960_CR16","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.fertnstert.2014.10.038","volume":"103","author":"J Donnez","year":"2015","unstructured":"Donnez J, Hudecek R, Donnez O, Matule D, Arhendt HJ, Zatik J, et al. Efficacy and safety of repeated use of ulipristal acetate in uterine fibroids. Fertil Steril. 2015;103(2):519\u201327.e3. https:\/\/doi.org\/10.1016\/j.fertnstert.2014.10.038.","journal-title":"Fertil Steril"},{"issue":"1","key":"960_CR17","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.fertnstert.2015.09.032","volume":"105","author":"J Donnez","year":"2016","unstructured":"Donnez J, Donnez O, Matule D, Ahrendt HJ, Hudecek R, Zatik J, et al. Long-term medical management of uterine fibroids with ulipristal acetate. Fertil Steril. 2016;105(1):165\u201373.e4. https:\/\/doi.org\/10.1016\/j.fertnstert.2015.09.032.","journal-title":"Fertil Steril"},{"issue":"4","key":"960_CR18","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.fertnstert.2018.06.044","volume":"110","author":"J Donnez","year":"2018","unstructured":"Donnez J. Liver injury and ulipristal acetate: an overstated tragedy? Fertil Steril. 2018;110(4):593\u20135. https:\/\/doi.org\/10.1016\/j.fertnstert.2018.06.044.","journal-title":"Fertil Steril"},{"issue":"12","key":"960_CR19","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1080\/14740338.2018.1550070","volume":"17","author":"J Donnez","year":"2018","unstructured":"Donnez J, Arriagada P, Marciniak M, Larrey D. Liver safety parameters of ulipristal acetate for the treatment of uterine fibroids: a comprehensive review of the clinical development program. Expert Opin Drug Saf. 2018;17(12):1225\u2013322. https:\/\/doi.org\/10.1080\/14740338.2018.1550070.","journal-title":"Expert Opin Drug Saf"},{"issue":"2","key":"960_CR20","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1111\/liv.12988","volume":"36","author":"L Dara","year":"2016","unstructured":"Dara L, Liu ZX, Kaplowitz N. Mechanisms of adaptation and progression in idiosyncratic drug induced liver injury, clinical implications. Liver Int. 2016;36(2):158\u201365. https:\/\/doi.org\/10.1111\/liv.12988.","journal-title":"Liver Int"},{"key":"960_CR21","unstructured":"European Medicines Agency. Suspension of ulipristal acetate for uterine fibroids during ongoing EMA review of liver injury risk. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/ulipristal-acetate-5mg-medicinal-products. Accessed Mar 2020."},{"key":"960_CR22","unstructured":"Ella [prescribing information]. Charleston (SC): Afaxys Pharma LLC; May 2018."},{"key":"960_CR23","unstructured":"European Medicines Agency. EMA starts review of Esmya for uterine fibroids: review triggered by cases of liver injury. https:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Referrals_document\/Esmya_20\/Procedure_started\/WC500239713.pdf. Accessed 1 Dec 2017."},{"issue":"1","key":"960_CR24","doi-asserted-by":"publisher","first-page":"55","DOI":"10.2165\/00002018-200932010-00005","volume":"32","author":"RJ Fontana","year":"2009","unstructured":"Fontana RJ, Watkins PB, Bonkovsky HL, Chalasani N, Davern T, Serrano J, et al. Drug-induced liver injury network (DILIN) prospective study: rationale, design and conduct. Drug Saf. 2009;32(1):55\u201368. https:\/\/doi.org\/10.2165\/00002018-200932010-00005.","journal-title":"Drug Saf"},{"issue":"1","key":"960_CR25","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1002\/hep.22620","volume":"49","author":"AD Brinker","year":"2009","unstructured":"Brinker AD, Wassel RT, Lyndly J, Serrano J, Avigan M, Lee WM, et al. Telithromycin-associated hepatotoxicity: clinical spectrum and causality assessment of 42 cases. Hepatology. 2009;49(1):250\u20137. https:\/\/doi.org\/10.1002\/hep.22620.","journal-title":"Hepatology"},{"issue":"14","key":"960_CR26","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1177\/1352458516688351","volume":"23","author":"MA Munoz","year":"2017","unstructured":"Munoz MA, Kulick CG, Kortepeter CM, Levin RL, Avigan MI. Liver injury associated with dimethyl fumarate in multiple sclerosis patients. Mult Scler. 2017;23(14):1947\u20139. https:\/\/doi.org\/10.1177\/1352458516688351.","journal-title":"Mult Scler"},{"issue":"11","key":"960_CR27","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1016\/0895-4356(93)90101-6","volume":"46","author":"G Danan","year":"1993","unstructured":"Danan G, Benichou C. Causality assessment of adverse reactions to drugs. I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol. 1993;46(11):1323\u201330. https:\/\/doi.org\/10.1016\/0895-4356(93)90101-6.","journal-title":"J Clin Epidemiol."},{"key":"960_CR28","unstructured":"LiverTox: clinical and research information on drug-induced liver injury. Roussel Uclaf Causality Assessment Method (RUCAM) in drug induced liver injury. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012; updated 20 November, 2019. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK548272\/. Accessed 15 Jun 2020."},{"issue":"1","key":"960_CR29","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3390\/ijms17010014","volume":"17","author":"G Danan","year":"2015","unstructured":"Danan G, Teschke R. RUCAM in drug and herb induced liver injury: the update. Int J Mol Sci. 2015;17(1):14. https:\/\/doi.org\/10.3390\/ijms17010014.","journal-title":"Int J Mol Sci"},{"key":"960_CR30","unstructured":"European Medicines Agency. Assessment report: procedure under Article 20 of Regulation (EC) No 726\/2004 resulting from pharmacovigilance data: Esmya. https:\/\/www.ema.europa.eu\/en\/documents\/variation-report\/esmya-h-c-2041-a20-0043-epar-assessment-report-article-20_en.pdf. Accessed 17 May 2018."},{"key":"960_CR31","first-page":"S111","volume":"105","author":"J Shon","year":"2019","unstructured":"Shon J, Yu C, Tran D. Exploration of hepatotoxicity potential and its plausible mechanism of specific progesterone-receptor modulators. Clin Pharmacol Ther. 2019;105:S111.","journal-title":"Clin Pharmacol Ther"},{"key":"960_CR32","unstructured":"European Medicines Agency. Esmya [summary of product characteristics]. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/esmya-epar-product-information_en.pdf. Accessed 25 Jul 2018."},{"issue":"7","key":"960_CR33","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1001\/jama.286.7.831","volume":"286","author":"DJ Graham","year":"2001","unstructured":"Graham DJ, Drinkard CR, Shatin D, Tsong Y, Burgess MJ. Liver enzyme monitoring in patients treated with troglitazone. JAMA. 2001;286(7):831\u20133. https:\/\/doi.org\/10.1001\/jama.286.7.831.","journal-title":"JAMA"},{"issue":"24","key":"960_CR34","doi-asserted-by":"publisher","first-page":"3081","DOI":"10.1001\/jama.286.24.3081","volume":"286","author":"L La Grenade","year":"2001","unstructured":"La Grenade L, Graham DJ, Nourjah P. Underreporting of hemorrhagic stroke associated with phenylpropanolamine. JAMA. 2001;286(24):3081.","journal-title":"JAMA"},{"issue":"13","key":"960_CR35","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1001\/jama.288.13.1588","volume":"288","author":"B Begaud","year":"2002","unstructured":"Begaud B, Martin K, Haramburu F, Moore N. Rates of spontaneous reporting of adverse drug reactions in France. JAMA. 2002;288(13):1588.","journal-title":"JAMA"},{"key":"960_CR36","unstructured":"LiverTox: clinical and research information on drug-induced liver injury. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012; updated 9 January, 2020. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK548773\/. Accessed 15 Jun 2020."}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-020-00960-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-020-00960-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-020-00960-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T17:11:24Z","timestamp":1659114684000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-020-00960-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,9]]},"references-count":36,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["960"],"URL":"https:\/\/doi.org\/10.1007\/s40264-020-00960-1","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,9]]},"assertion":[{"value":"9 July 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Sarah Kang, Allen Brinker, S. Christopher Jones, Lara Dimick-Santos, and Mark\u00a0I. Avigan have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was granted an exemption for review by the US Food and Drug Administration Institutional Review Board.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"All data generated and analyzed during this research are included in this article and its supplementary information files.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}